Search

Your search keyword '"Dingli, David"' showing total 2,880 results

Search Constraints

Start Over You searched for: Author "Dingli, David" Remove constraint Author: "Dingli, David"
2,880 results on '"Dingli, David"'

Search Results

1. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events

2. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

4. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

6. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

7. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

9. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

10. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

12. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

13. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies

14. Muscle and fat composition in patients with newly diagnosed multiple myeloma

15. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

16. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

19. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

23. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

24. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

25. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.

26. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

28. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

29. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

30. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.

31. Outcomes after biochemical or clinical progression in patients with multiple myeloma

32. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

33. Metformin and cytokine release syndrome after immune effector cell therapy.

34. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.

35. First relapse in patients with multiple myeloma: Outcomes and predictors.

36. Class comparison of BCMA-directed therapies in relapsed multiple myeloma.

37. Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.

39. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

40. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

42. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

43. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

44. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States

46. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

47. Kidney Transplant Outcomes of Patients With Multiple Myeloma

Catalog

Books, media, physical & digital resources